The following is a summary of “Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving ...

ImmunityBio has entered into a supply agreement and partnership with BeiGene for conducting a confirmatory Phase III ResQ201A-NSCLC trial combining tislelizumab and Anktiva to treat advanced or ...

Researchers investigated immune-related adverse effects and characteristics that may predict their incidence in patients receiving ICIs for gastrointestinal cancers.

Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

"What is a tumor?" This is the fundamental question to answer if we want to treat cancer effectively. Our vision of cancer ...

A team led by the Cancer Immunogenomics group at the Josep Carreras Leukaemia Research Institute, the Computational Biology group at the Barcelona Supercomputing Center and the Germans Trias i Pujol ...

New research highlights a link between immune checkpoint inhibitors (ICIs) and an increased risk of autoimmune diseases, including rheumatoid arthritis, emphasizing the need for vigilance among ...

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

Researchers aim to validate the AI tool SCORPIO in prospective studies and eventually seek FDA clearance to sell it as a commercial tool in the US.

Can pollution cause it? What about inflammation? And how do tumors spread? Here’s what scientists are learning about this ...